A 47-year-old male patient presented in March 2016 to our unit with a palpable painless left supraclavicular mass. A whole-body contrastenhanced computed tomography (CT) scan revealed a left supraclavicular lymphadenopathy, transverse colon thickening (3 cm), multiple chest and abdominal lymphadenopathies, and peritoneal carcinomatosis. Colonoscopy revealed a bleeding area at 15 cm from the anal verge; biopsy was performed, and the result was negative for a primary cancer.
EGFR inhibitor as second-line therapy in a patient with mutant RAS metastatic colorectal cancer: circulating tumor DNA to personalize treatment / Gazzaniga, Paola; Raimondi, Cristina; Urbano, Federica; Cortesi, Enrico. - In: JCO PRECISION ONCOLOGY. - ISSN 2473-4284. - 2:(2018), pp. 1-6. [10.1200/PO.17.00277]
EGFR inhibitor as second-line therapy in a patient with mutant RAS metastatic colorectal cancer: circulating tumor DNA to personalize treatment
Gazzaniga Paola
Primo
;Raimondi CristinaSecondo
;Urbano FedericaPenultimo
;Cortesi EnricoUltimo
2018
Abstract
A 47-year-old male patient presented in March 2016 to our unit with a palpable painless left supraclavicular mass. A whole-body contrastenhanced computed tomography (CT) scan revealed a left supraclavicular lymphadenopathy, transverse colon thickening (3 cm), multiple chest and abdominal lymphadenopathies, and peritoneal carcinomatosis. Colonoscopy revealed a bleeding area at 15 cm from the anal verge; biopsy was performed, and the result was negative for a primary cancer.| File | Dimensione | Formato | |
|---|---|---|---|
|
Gazzaniga_EGFR-inhibitor_2018.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
904.04 kB
Formato
Adobe PDF
|
904.04 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
